International journal of nanomedicine · 2026
Melatonin-Loaded Sacchachitin Nanofiber Hydrogel as a Novel Non-Steroidal Platform for Atopic Dermatitis Therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Chien-Ju, Wen Bang-Yu, Liang Yu-Kai, You Wen-Chen, Ho Hsiu-O, Sheu Ming-Thau, Lin Hong-Liang, Chen Ling-Chun
Аннотация
INTRODUCTION: Atopic dermatitis (AD) is a chronic inflammatory skin disease commonly managed with topical corticosteroids or calcineurin inhibitors, which may raise concerns with long-term use. Safe, non-steroidal topical therapies capable of restoring skin barrier function while modulating local immune responses remain limited.
METHODS: A sacchachitin nanofiber (SCNF)-based hydrogel incorporating melatonin (MSC) was developed and evaluated for physicochemical properties, stability, and therapeutic efficacy using a 2,4-dinitrochlorobenzene (DNCB)-induced NC/Nga mouse model of AD. Clinical scores, histological features, and immunological biomarkers were assessed.
RESULTS: Among the tested formulations, the melatonin-loaded hydrogel (MSC) demonstrated the most pronounced therapeutic efficacy compared with other formulations, significantly reducing AD severity, epidermal hyperplasia, mast cell infiltration, and Th2-associated markers including IgE, IgG1, and IL-4. Melatonin remained chemically stable for at least 31 days and did not compromise hydrogel mechanical or adhesive properties. In this system, sacchachitin nanofibers primarily function as a structural scaffold, whereas melatonin provides the principal biological and immunomodulatory activity.
CONCLUSION: The melatonin-loaded SCNF hydrogel represents a promising non-steroidal and biocompatible topical platform for AD. In this system, SCNF primarily serves as a structural scaffold, whereas melatonin provides immunomodulatory and anti-inflammatory activity. These findings support further translational investigation.
METHODS: A sacchachitin nanofiber (SCNF)-based hydrogel incorporating melatonin (MSC) was developed and evaluated for physicochemical properties, stability, and therapeutic efficacy using a 2,4-dinitrochlorobenzene (DNCB)-induced NC/Nga mouse model of AD. Clinical scores, histological features, and immunological biomarkers were assessed.
RESULTS: Among the tested formulations, the melatonin-loaded hydrogel (MSC) demonstrated the most pronounced therapeutic efficacy compared with other formulations, significantly reducing AD severity, epidermal hyperplasia, mast cell infiltration, and Th2-associated markers including IgE, IgG1, and IL-4. Melatonin remained chemically stable for at least 31 days and did not compromise hydrogel mechanical or adhesive properties. In this system, sacchachitin nanofibers primarily function as a structural scaffold, whereas melatonin provides the principal biological and immunomodulatory activity.
CONCLUSION: The melatonin-loaded SCNF hydrogel represents a promising non-steroidal and biocompatible topical platform for AD. In this system, SCNF primarily serves as a structural scaffold, whereas melatonin provides immunomodulatory and anti-inflammatory activity. These findings support further translational investigation.